MetaVia Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTVA research report →
Price Chart
About the company
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
- CEO
- Hyung Heon Kim
- IPO
- 2016
- Employees
- 8
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on MTVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.81M
- P/E
- -0.31
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 2.80
- EV/EBITDA
- 0.11
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -265.53%
- ROIC
- -628.12%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-19,000+0.0%
- Op Income
- $-13,708,000
- Net Income
- $-12,973,000+53.0%
- EPS
- $-7.35+81.2%
- OCF Growth
- +36.5%
- FCF Growth
- +36.5%
- 52W High
- $13.42
- 52W Low
- $0.97
- 50D MA
- $1.40
- 200D MA
- $1.58
- Beta
- 0.96
- RSI (14)
- 38
- Avg Volume
- 113.44K
No earnings-call transcripts are available for MTVA yet.
- Free Float
- 71.2%
- Shares Outstanding
- 6.74M
- Float Shares
- 4.80M
of shares held by institutions
17 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jane Street Group, LLC | 92.14K | ▼ 31.44K |
| Citadel Advisors LLC | 61.21K | ▲ 61.21K |
| Vanguard Fiduciary Trust Co | 37.80K | ▲ 30.86K |
| Geode Capital Management, LLC | 33.75K | ▲ 12.44K |
| Virtu Financial LLC | 29.93K | ▲ 29.93K |
| Vanguard Group Inc | 20.09K | ▲ 20.09K |
| Vanguard Capital Management LLC | 19.32K | ▲ 10.40K |
| Hrt Financial LP | 15.61K | ▲ 15.61K |
| Aries Wealth Management | 10.00K | 0 |
| Tower Research Capital LLC (Trc) | 2.67K | ▲ 451 |
| Fmr LLC | 750 | ▲ 750 |
| Comprehensive Financial Planning, Inc./Pa | 129 | ▲ 129 |
Held by 4 ETFs
Biggest fund positions in MTVA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 12, 26 | Browne Sarah Kaplan | other | 53,000 |
| Oct 12, 26 | Browne Sarah Kaplan | other | 0 |
| Jun 8, 26 | Tursi James Patrick | other | 17,186 |
| Jun 8, 26 | STRICKLAND D GORDON | other | 17,186 |
| Jun 8, 26 | Salsbury Michael | other | 17,186 |
| Jun 8, 26 | GROVES JASON L | other | 17,186 |
| Jun 8, 26 | KOVEN ANDREW I | other | 17,186 |
| Jun 8, 26 | Glickman Mark A | other | 17,186 |
| Jan 23, 26 | Woodworth Marshall H | other | 28,000 |
| Jan 23, 26 | Kim Hyung Heon | other | 32,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MTVA coverage
Recent articles, reports, and earnings notes.
No research on MTVA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MTVA report →MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
prnewswire.com · Nov 17
MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026
prnewswire.com · Nov 16
MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update
prnewswire.com · Nov 13
MetaVia's Potential Drug Candidate Cuts Serum Uric Acid and Liver Fat
benzinga.com · Nov 12
MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial
prnewswire.com · Nov 12
MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026
prnewswire.com · Nov 9
MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data
prnewswire.com · Nov 5
MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
prnewswire.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.